Signalife receives $102m lifeline:
This article was originally published in Clinica
Biomedical signal monitoring specialist Signalife has received a welcome financial boost in the shape of a $102m funding from YA Global Investments. The Greenville, South Carolina-based company was issued with an AMEX deficiency letter in June, stating that the company's shareholder equity price had fallen below the minimum threshold for companies with market caps of less than $50m. Signalife has received $2m upfront from the sale of common stock and warrants to YA, and has entered a standby equity distribution agreement with the investment firm that will see the sale of $100m in additional stock over the next three years. As well as repairing the company's stock market position, the funding will also help sales and marketing of its lead product, the Fidelity 100 heart monitor, designed to detect early signs of cardiovascular disease.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.